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We report 2 cases of Ebola viral disease (EVD) in pregnant women
who survived, initially with intact pregnancies. Respectively 31–32
days after negativation of the maternal blood EVD-polymerase
chain reaction (PCR) both patients delivered a stillborn fetus
with persistent EVD-PCR amniotic fluid positivity.
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In March 2014, the World Health Organization declared an
Ebola virus disease (EVD) outbreak in Guinea, Guéckédou.
The outbreak, which subsequently spread to Sierra Leone, Libe-
ria, Senegal, Mali, and Nigeria, is the largest in history, currently
with 27c965 cases and 11c298 deaths reported [1]. The Zaire
strain is responsible for the current outbreak [2], with a 64.3%
case fatality rate in the 3 most affected countries, Liberia, Sierra
Leone, and Guinea, during the first 9 months of this epidemic
[3]. In the literature, mortality in pregnant women is extremely
high. Case series from prior epidemics report an 89%–93% case
fatality rate among pregnant women [4, 5], and perinatal mor-
tality is 100%. No reports have been published of neonates sur-
viving transplacental EVD for longer than 19 days [6].
Ebola virus (EBOV) transmission occurs through direct con-
tact with body fluids [7]. EBOV has been detected in a variety of
body fluids including blood, saliva, urine, sperm, tears, sweat,
breast milk, vomit, and excreta [8]. There is a paucity of data
on virus persistence in pregnant mothers who survive the infec-
tion. Here, we report the cases of 2 pregnant women, one from
Guinea (Guéckédou) and one from Sierra Leone (Kissi, Freetown),
who had a stillbirth after recovering from infection and in
whom EBOV RNA in amniotic fluid, umbilical cord blood,
and placenta was detected 32 and 31 days, respectively, after dis-
appearance of EBOV RNA from maternal blood.
Case 1 Description
In September 2014, a 40-year-old G11P10 4-month pregnant
woman with only term normal births in her history was ad-
mitted to an Médecins Sans Frontières (MSF)-managed Ebola
treatment center (ETC) in Guéckédou, Guinea. She complained
of several days of abdominal pain and diarrhea and was febrile
(39°C). A real-time reverse transcription–polymerase chain re-
action (RT–PCR) for EBOV RNA (L gene, Realstar filovirus
screen, RT–PCR kit 1.0, Altona Diagnostics, Hamburg, Germa-
ny) on whole blood was positive on 9 September 2014 (Table 1).
Two malaria rapid diagnostic tests (RDTs) were negative. The
patient recovered without complications. Five days after admis-
sion, the EBOV RT–PCR on maternal blood was twice negative
(Table 1). During admission, she described daily fetal move-
ments. The fetal heart rate was repeatedly checked with Doppler
sonography and remained within the normal range. As she was
afebrile and the RT–PCR for EBOV RNA in maternal blood was
twice negative, she was technically eligible for discharge from
the ETC. However, the treating health workers were concerned
about possible EBOV persistence in the placenta or amniotic
fluid based on previous experience with EBOV-positive preg-
nant women [9]. Many women in Guinea deliver at home
with a traditional birth attendant (TBA), so the potential danger
of infecting the TBA, healthcare workers, or other family mem-
bers if the amniotic fluid were to remain infectious was critical
in development of a delivery plan. One option that the treat-
ment team proposed was to terminate the pregnancy, for public
health reasons, in an ETC with staff wearing full personal pro-
tective equipment in order not to risk her delivering at home or
in an inadequately equipped primary healthcare facility. The
patient and family declined. As an alternative solution, the
team proposed that the patient remain near the ETC until de-
livery. During subsequent weeks, the patient repeatedly report-
ed normal fetal movements. However, on 16 October 2014, 32
days after maternal blood first tested negative using EBOV RT–
PCR, the patient started to bleed vaginally. She was transferred
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back to the ETC and had a spontaneous delivery of a 5-month
stillborn fetus. After administration of 10 IU oxytocin, blood
loss in the postpartum was normal. EBOV RT–PCR on placen-
ta, umbilical cord blood, and amniotic fluid after rupturing of
membranes were all highly positive (Table 1). The mother left
the ETC 1 week later in good condition and with condoms as a
component of family planning.
Case 2 Description
On 7 March 2015, a 22-year-old G3P0 woman approximately 5
months pregnant was admitted from a quarantine home to an
MSF-managed ETC in Kissi, Freetown, Sierra Leone. Per Sierra
Leone national Ebola response policy, the patient’s household
had been placed under quarantine for 21 days due to an in-
house confirmed Ebola death. Her obstetric history consisted
of 2 first trimester miscarriages.
On admission, the patient complained of anorexia, muscle
pain, and joint pain. The patient tested negative on malaria
RDT. She denied vaginal bleeding, uterine contractions, or
loss of fluid and reported good fetal movement. The patient
was initially afebrile but later had a temperature of 38.3°C dur-
ing the first 24 hours of her hospital stay. Blood samples were
taken on 8 March and 9 March, and RT–PCR for EBOV RNA
(L gene, Realstar filovirus screen, RT–PCR kit 1.0) was positive
(see Supplementary Materials). She had an uncomplicated re-
covery during her hospital stay and reported frequent fetal
movements. Fetal heart rate was auscultated by Doppler and
found to be within normal range.
Following a negative RT–PCR test on 14 March, the patient
and her family were counseled extensively on the risk of a still-
birth and that her fetus, placenta, and amniotic fluid may
remain positive for the EBOV. The patient opted for expectant
management with routine care and initially agreed to remain in
the ETC for surveillance. On 21March 2015 the patient request-
ed to leave the ETC and was discharged against medical advice
to her home, which was still under quarantine.
Upon discharge, the woman and her family were advised to
self-isolate and to call in the event of any abdominal pain, vag-
inal bleeding, discharge, or leaking of amniotic fluid while at
home. The patient was called twice daily by a trained healthcare
worker and was asked to present weekly to the ETC for an ex-
amination by the clinical staff.
On 13 April, 3 weeks post-discharge, the patient presented to
the ETC. An ultrasound confirmed an intrauterine fetal death.
The patient initially declined intervention. On the morning of
14 April the patient reported abdominal pain and was noted to
have leaking fluid. Misoprostol 200 μg buccal was given every 4
hours. The patient expelled the placenta and fetus within the
amniotic sac approximately 30 minutes after the second dose
of misoprostol. The maternal surfaces of the placenta and am-
niotic sac were swabbed for the EBOV RT–PCR assay; only the
placenta tested positive. Maternal blood tested negative for
EBOV RNA on 15 April and 17 April, and the patient was dis-
charged from the ETC on 17 April in good condition.
Ethics
The National Committee of Ethics inMedical Research of
Guinea approved the use of diagnostic leftover samples and
corresponding patient data for this study (permit N°11/
CNERS/14). As the samples had been collected as part of
the public health response to contain the outbreak in Guinea,
informed consent was not obtained from patients.
DISCUSSION
These 2 cases highlight several challenges in caring for pregnant
women with EVD. Both patients survived EVD and initially had
live second trimester fetuses in utero following cure. Limited pub-
lishedMSF data show a persistence of EBOV in amniotic fluid for
an unknown duration after negative RT–PCR tests for EBOV in
maternal blood [9]. Thus, at the moment of rupture of mem-
branes, delivery, or in the postpartum, convalescent pregnant
women could be possible sources of infection for health staff
and those in the community. There is also a paucity of data on
duration of fetal survival in utero, and a neonate surviving trans-
placental EVD has not been documented [6]. These cases from
Guinea and Sierra Leone also posed difficult ethical dilemmas
for the treating healthcare workers. If these patients were to be
discharged and subsequently delivered at home or in a health
center, they could have infected their family members, TBAs,
or healthcare providers at the moment of membrane rupture
or during delivery. The TBA or healthcare provider attending
the delivery could have become a source of secondary EBOV
transmission and enhance the further spread of EVD [10].
After long discussions of these 2 cases, one option proposed
was termination of the pregnancy for public health reasons. In
both cases, the family and the patient declined termination,
and other solutions were necessary. In Guinea a small wooden
house was built next to the ETC where the family visited the
Table 1. Ebola Virus Real-Time Reverse Transcription–Polymerase Chain





9 September Maternal blood Positive (22.3)
14 September Maternal blood Negative
15 September Maternal blood Negative
6 October Vaginal swab after rupture of
amniotic sac
Positive (28.9)
17 October Amniotic fluid Positive (22.2)
17 October Placental swab Positive (18.4)
17 October Cord blood Positive (15.8)
The lower the cycle threshold (Ct) value, the higher the virus load. A Ct value of 20 roughly
corresponds to 108 EBOV RNA copies/mL of specimen.
Abbreviation: EBOV, Ebola virus.
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patient and where the patient remained until her labor started. In
Sierra Leone it was originally proposed that the patient remain
hospitalized until delivery. She later declined and returned to
her home. The team called her twice a day by phone.
These 2 cases add to the growing data on EBOV persistence
in the body for more than 1 month after disappearance of
EBOV RNA from blood. At the beginning of the epidemic, rou-
tine pregnancy testing was not standard at ETC entry, which
meant that some early pregnancies may have passed unnoticed
and thus potentially became a risk for infection in the commu-
nity if a convalescent woman miscarried at home following
discharge.
CONCLUSION
Managing pregnant women in an Ebola epidemic remains ex-
tremely complex. Research on possible infectivity of amniotic
fluid after convalescence of themother should be prioritized.We
strongly urge healthcare workers who care for EBOV-positive
pregnant women to advocate for delivery in an ETC, even
after the convalescence of the mother, in order to prevent
cross-infection due to EBOV persistence in amniotic fluid.
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